drugset / Trial / NCT07723703
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.
Timeline
- Start
- 2026-10-16
- Primary completion
- 2028-12-04
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMX-883 | Unknown | — | Oral |
| Subject | Posaconazole | Small molecule | — | Oral |